Tuesday, 3 December 2013 - 14:35

World AIDS Day is a very important day internationally. The Treatment Action Campaign (TAC) and SECTION27 respect the dignity of the day and the decision of SANAC and the National Department of Health to use it to promote voluntary medical male circumcision (VMMC) and relaunch HIV Counselling and Testing (HCT). But the day also requires that we speak honestly about the challenges that face the response to HIV in SA and internationally.
The day belongs to activists as much as it does to governments and UNAIDS who have taken over the day and today seem to resent those of us who...

Read more
Sunday, 1 December 2013 - 12:50

PIET RETIEF - Over one thousand Treatment Action Campaign members marched to the official World AIDS Day event in Piet Retief today to draw attention to the real challenges faced by people living with HIV/AIDS (PWAs) in the province, specifically critical drug stock-outs and a collapsing public health system.
At short notice this morning TAC was grateful to be offered a meeting with Deputy President Kgalema Motlanthe so we could address these critical issues.
However, two attempts to meet with the Deputy President failed and TAC has as a result made it clear...

Read more
Friday, 29 November 2013 - 11:51

HIV struggle undermined by medicine stockouts and mismanagement
MECs for health must be held accountable for delivery of NSP targets and state of Provincial health systems
On World AIDS Day, December 1st 2013 the Treatment Action Campaign (TAC) will not be celebrating. We recognize that we have made very significant progress in the fight against HIV. But medicines stock-outs, corruption, mismanagement and an apparent lack of political will to deal with these problems are undermining our struggle against HIV.

Read more
Thursday, 28 November 2013 - 14:02

Stop Stock Outs consortium calls on Department of Health to face reality and end stock outs
28 November
JOHANNESBURG – The success and integrity of South Africa’s massive HIV programme is threatened by an invisible and insidious reality: crisis-level stock outs of life-saving medicines which have affected one in five facilities serving 420,000 of the 2.4 million people who rely on public health services for their antiretroviral treatment (ART).
20% of the 2,139 health facilities responding to the first and largest ever national...

Read more
Tuesday, 19 November 2013 - 17:04

- Janssen must run a Phase III trial of bedaquiline urgently
- More investment in TB drugs and diagnostics urgently needed
The current standard of care for multi-drug resistant tuberculosis (MDR-TB) consists of poorly tested drugs with horrible side-effects. We are desperately in need of new properly tested TB drugs.
Bedaquiline, made by the pharmaceutical company Janssen (a subsidiary of Johnson & Johnson), is a promising drug for treating drug-resistant TB.  Two phase II trials have shown compelling evidence that the drug is effective at...

Read more